Twelve months outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: observational study data

被引：0
|
作者：
Gillies, Mark C. [1 ]
Walton, Richard [1 ]
Arnold, Jennifer [2 ]
Essex, Rohan [3 ]
Morlet, Nigel [4 ]
Barthelmes, Daniel [1 ,5 ]
机构：
[1] Univ Sydney, Ophthalmol, Sydney, NSW, Australia
[2] Marsden Eye Specialists, Parramatta, NSW, Australia
[3] Canberra Hosp, Dept Ophthalmol, Garran, ACT, Australia
[4] Univ Western Australia, Dept Populat Hlth, Perth, WA, Australia
[5] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2016年 / 57卷 / 12期
基金：
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
523
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study
    Gillies, Mark C.
    Vuong Nguyen
    Daien, Vincent
    Arnold, Jennifer J.
    Morlet, Nigel
    Barthelmes, Daniel
    OPHTHALMOLOGY, 2016, 123 (12) : 2545 - 2553
  • [2] Twelve-month outcomes of ranibizumab versus aflibercept for neovascular age-related macular degeneration: an observational study.
    Gillies, Mark C.
    Daien, Vincent
    Vuong Nguyen
    Arnold, Jennifer J.
    Morlet, Nigel
    Barthelmes, Daniel
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [3] Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration (vol 123, pg 2545, 2016)
    不详
    OPHTHALMOLOGY, 2017, 124 (05) : 746 - 746
  • [4] TWELVE-MONTH OUTCOMES OF RANIBIZUMAB VERSUS AFLIBERCEPT FOR NEOVASCULAR AGE- RELATED MACULAR DEGENERATION: AN OBSERVATIONAL STUDY
    Gillies, Mark
    Vuong Nguyen
    Daien, Vincent
    Arnold, Jennifer
    Morlet, Nigel
    Barthelmes, Daniel
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 44 : 29 - 29
  • [5] Twelve-month outcomes of aflibercept versus ranibizumab for neovascular age-related macular degeneration (AMD)
    Almuhtaseb, Hussein
    Michaels, Luke
    Vardarinos, Thanos
    Lotery, Andrew J.
    EYE, 2018, 32 (11) : 8 - 10
  • [6] Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study
    Jae Hui Kim
    Dong Won Lee
    Young Suk Chang
    Jong Woo Kim
    Chul Gu Kim
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254 : 2101 - 2109
  • [7] Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study
    Kim, Jae Hui
    Lee, Dong Won
    Chang, Young Suk
    Kim, Jong Woo
    Kim, Chul Gu
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 254 (11) : 2101 - 2109
  • [8] Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
    Jin, Ki Won
    Kim, Jae Hui
    Park, Jun Young
    Park, Sang Jun
    Park, Kyu Hyung
    Lee, Joo Yong
    Woo, Se Joon
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [9] Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
    Ki Won Jin
    Jae Hui Kim
    Jun Young Park
    Sang Jun Park
    Kyu Hyung Park
    Joo Yong Lee
    Se Joon Woo
    Scientific Reports, 11
  • [10] RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Data from an Observational Study
    Vaze, Anagha
    Vuong Nguyen
    Daien, Vincent
    Arnold, Jennifer J.
    Young, Stephanie H.
    Cheung, Chui M.
    Lamoureux, Ecosse
    Bhargava, Mayuri
    Barthelmes, Daniel
    Gillies, Mark C.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (10): : 1954 - 1961
12345